The Cancer Letter

Inside information on cancer research and drug development

In Brief

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Jennifer Munson has been named director of the Fralin Biomedical Research Institute at VTC’s Cancer Research Center in Roanoke, VA.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
Clinical Roundup

USP1 inhibitor combination shows manageable safety profile, anti-tumor activity in metastatic solid tumors in phase I study preliminary data

Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account